SAN DIEGO, Feb. 22 (GenomeWeb News) - Following a talk at the Clinical Genomics conference here last week, Walter Koch, senior director of Roche's pharmacogenomics department, provided a few details concerning the company's upcoming leukemia microarray and p53 AmpliChip products, which are being produced using technology the company licensed from Affymetrix.
"We will need a diagnostic for resequencing p53 if [Roche's] MDM2-inhibitors make it through trials," Koch said of the company's AmpliChip p53 mutational analysis test. The cancer drugs are currently "close to Phase I," he said.
Koch also clarified the capabilities of an upcoming leukemia microarray, which will classify tumor cells into one of 20 subtypes, he said.
The leukemia classification microarray is slated for rollout during 2005 and into 2006, while the AmpliChip p53 test has been targeted for research use in 2006.